Business Wire

MA-ONAPSIS

10.5.2022 15:02:13 CEST | Business Wire | Press release

Share
Onapsis Announces New Offering to Jumpstart Security for SAP Customers

Onapsis , the leader in business-critical application cybersecurity and compliance, today announced the release of Onapsis Assess Baseline. In a world where business-critical applications are under attack every day, this new offering accelerates organizations’ abilities to kickstart their SAP vulnerability management programs by better aligning with the SAP Security Baseline.

The exponential growth of targeted ransomware and the increased threat of cyber warfare due to global conflict means that organizations must re-evaluate how they secure their most critical systems. Amid this evolving, more aggressive threat landscape , companies struggle to keep up with patching the growing number of vulnerabilities exploited by threat actors to gain access to their business-critical applications. Onapsis Assess Baseline empowers companies of any size to accelerate time-to-value by simplifying deployment with a new SaaS-based, zero-footprint model and focusing on a core, targeted set of critical vulnerabilities as first steps on their journey to ensure cybersecurity, compliance, and availability of their SAP applications. When organizations are ready to take on more, Onapsis Assess Baseline offers easy expansion to additional scope for vulnerability management as well as capabilities for continuous threat monitoring and application security testing.

Key Organizational Benefits with Onapsis Assess Baseline:

  • Reduce Implementation Overhead with an Accelerated Deployment: Whether in their own cloud, on-premises, or through Onapsis’ SaaS platform, Assess Baseline offers quick deployment and implementation with zero footprint scanning.
  • Accelerate Time-to-Value for SAP Vulnerability Management: Onapsis SaaS users can scan with Assess Baseline against the SAP-recommended security baseline requirements for an organization’s SAP systems within hours. The scans deliver powerful context around critical vulnerabilities, instructions on how to mitigate, and confidence that patches were applied, saving valuable resource time.
  • Technology that Scales and Grows When You’re Ready: Deploy where you want. Scan across the entire SAP landscape. Start small and target the most critical systems first, get them aligned to a baseline, and then expand the security scope across the organization on your terms.

“Securing business-critical applications has always been challenging, but there’s a larger bullseye on the backs of organizations today - more than ever before - as sophisticated threat actors increasingly target Enterprise Resource Planning (ERP) systems,” said Mariano Nunez, CEO of Onapsis. “We have successfully helped the world’s largest and most sophisticated organizations integrate their business applications into their cybersecurity and compliance programs. Now, Assess Baseline makes it easy for customers who are getting started with their SAP application security programs to quickly and effectively jumpstart protecting the applications that power their businesses.”

The Onapsis Platform secures the critical SAP applications that keep the global economy running. The platform is purpose-built to deliver impactful vulnerability management, advanced threat detection, custom code inspection, and automated compliance that enables global organizations to accelerate their business and digital transformation initiatives. The Onapsis Platform is deeply informed by the latest threat intelligence and security guidance from the Onapsis Research Labs. This market-leading team has discovered more than 800 zero-day vulnerabilities and is responsible for multiple critical global CERT alerts.

“Today’s threat landscape requires a holistic approach to securing business-critical SAP applications such as ERP software,” said Steve Biskie, national ERP risk and automation services leader with RSM US LLP. “It is exciting to see Onapsis continuing to innovate its solutions to assist companies on their security maturity journey. The new Baseline license can help pave the way for more organizations to have an entry point into vulnerability management for SAP applications that could help keep their critical data and applications safe and compliant.”

Attending the SAP Sapphire conference? Visit the Onapsis booth to learn more: #PA219

To schedule a time to speak with an Onapsis expert while at Sapphire, please visit: https://onapsis.com/sapphire-22

About Onapsis

Onapsis protects the business-critical applications that run the global economy, from the core to the cloud. The company’s cybersecurity and compliance solution offering, The Onapsis Platform, uniquely delivers vulnerability management, threat detection and response, change assurance, and continuous compliance for business-critical applications from leading vendors such as SAP, Oracle, Salesforce, and other SaaS platforms.

Onapsis is headquartered in Boston, MA, with offices in Heidelberg, Germany and Buenos Aires, Argentina, and proudly serves more than 300 of the world’s leading brands, including 20% of the Fortune 100, 6 of the top 10 automotive companies, 5 of the top 10 chemical companies, 4 of the top 10 technology companies, and 3 of the top 10 oil and gas companies.

The Onapsis Platform is powered by the Onapsis Research Labs, the team responsible for the discovery and mitigation of more than 800 zero-day vulnerabilities in business-critical applications. The reach of our threat research and platform is broadened through leading consulting and audit firms such as Accenture, Deloitte, IBM, PwC, and KPMG — making Onapsis solutions the standard in helping organizations protect their cloud, hybrid, and on-premises business-critical information and processes. For more information, connect with us on Twitter or LinkedIn , or visit us at https://onapsis.com/ .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye